1月7日，A股三大股指早盘震荡走高，创业板盘初一度创下阶段高点，存储器、有色金属拉升。港股恒指、恒科指 早盘下跌，科网股多数调整。债市方面，国债期货延续跌势。商品方面，国内商品期货全线上涨，沪银涨超3%。核 心市场走势： | 代码 | 名称 | 两日图 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | --- | | 000001 | 上证指数 | 15 V | 4092.52 | 8.86 | 0.22% | | 399001 | 深证成指 | 1 | 14086.74 | 64.19 | 0.46% | | 399006 | 创业板指 | A W | 3336.66 | 17.37 | 0.52% | | 000300 | 沪深300 | 145 V | 4796.04 | 5.34 | 0.11% | | 000016 | FiFF50 | Company of Children | 3160.64 | 1.88 | 0.06% | | 000680 | 科创综 | 11.54 | 1735.13 | 14.73 | 0.86% | | 000688 | ...

新年首个交易日，A股直接点燃开门红行情！ 1月5日收盘，沪指涨1.38%收复4000点，走出12连阳；深证成指涨2.24%，创业板指涨2.85%，北证50指 数涨1.80%。沪深北三市成交25672亿元，较上个交易日放量5015亿元。全市场超4100只个股上涨，超 120股涨停。 创新药概念股集体大涨，冠昊生物以20%幅度涨停，板块热度持续升温； | | 1992年以来沪指连阳时间记录 | | --- | --- | | 连阳长度 | 时间区间 | | 12连阳 | 2025.12.17-2026.1.5 | | 11连阳 | 2017.12.28-2018.1.12 | | 11连阳 | 2006.6.15-2006.6.29 | | 11连阳 | 1992.5.5-1992.5.25 | | 12连阳 | 1992.2.25-1992.3.11 | | | 数据来源: Choice | 此外，游戏、商业航天、军工装备等板块盘中均表现强劲。 来源：上海证券报 沪指2025年12月17日至2026年1月5日实现日线12连阳，创1992年3月以来最长连阳纪录。1992年3月以 来，出现过三次11连阳，分别是在1 ...

今日（2026年1月2日），港股市场迎来近17年最强开局。 截至收盘，恒生指数大涨707.93点，以26338.47点报收，涨幅2.76%，创下2009年以来最强开局表现。2009年1月2日， 当时恒指单日暴涨4.55%。 此外，恒生科技指数表现更强，截至收盘，恒生科技指数报收于5736.44点，上涨220.46点，涨幅达4%。 摩根士丹利：恒指最高看到34700点 摩根士丹利对港股也较为乐观。根据摩根士丹利发布的策略报告，2026年将是2025年高回报后的稳定之年，指数上涨空 间较为温和，同时将伴随适度的每股盈利增长，估值也将稳定在较高区间。背后支撑因素包括中国在全球科技竞赛中重 新站稳脚跟，以及贸易紧张局势有所缓解。 从行业来看，各类行业全线飘红，半导体、国防军工、软件服务、家电领涨。 | | | Wind香港二级行业指数 | | | | --- | --- | --- | --- | --- | | 半导体 | 国防军工 | 软件服务 | 家电川 | 钢铁川 | | 7.87% | 7.78% | 4.18% | 3.99% | 3.59% | | 可选消费零售 | 有色金属 | 非银金融 | 耐用消费 ...

Market Performance - The Hong Kong stock market has experienced its strongest opening in nearly 13 years, with the Hang Seng Index rising by 707.93 points to close at 26,338.47, marking a 2.76% increase, the best performance since January 2, 2013 [1] - The Hang Seng Tech Index performed even better, closing at 5,736.44 points, up 220.46 points, with a 4% increase [3] Sector Performance - All sectors showed positive performance, with semiconductors, defense, software services, and home appliances leading the gains [5] - Specific sector gains included: - Defense and military industry: 7.87% - Software services: 7.78% - Home appliances: 4.18% - Consumer discretionary retail: 3.53% [6] Key Stocks - Notable stocks in the Hang Seng Tech Index included: - Hua Hong Semiconductor and Baidu Group, both rising over 9% - NetEase up over 6% - Ctrip up over 5% - Core companies Alibaba and Tencent both up over 4% [6] Analyst Predictions - Analysts noted that the strong performance of the Hong Kong market was driven by local and foreign funds, despite the absence of southbound capital [7] - DBS Bank predicts the Hang Seng Index could reach 36,500 points in the most optimistic scenario, representing an increase of over 10,000 points from current levels [7][8] - Morgan Stanley forecasts a target of 34,700 points for the Hang Seng Index, supported by stable earnings growth and a favorable global economic environment [9][10] - UBS sets a target of 30,000 points for the Hang Seng Index, driven by continued positive factors from 2025 [11] Investment Strategies - Analysts suggest a balanced investment strategy for 2026, focusing on sectors with growth certainty such as AI hardware while maintaining high-dividend assets for hedging [14] - The market is expected to see a second round of valuation recovery, driven by internal and external factors, including policy support and improved corporate earnings [18] - Key investment themes include technology, healthcare, and resource sectors, with a focus on companies with strong earnings visibility and valuation flexibility [18][19]

以下文章来源于港股解码 ，作者燕十四 港股解码 . 香港财华社明星专栏，20年专注港股，金融大咖汇聚，分析投资价值，做一个有态度、有深度、有意思 的原创财经新媒体！ 2025年，港、A两市的创新药赛道强势回暖，成为市场热门板块，三生国健（688336.SH）、 恒瑞医药（01276.HK）、百济神州（06160.HK）等创新药概念走势强劲。 作为科创板创新药企代表， 百利天恒（688506.SH）也表现不俗，年内累涨逾70%，上市至今 则飙升逾10倍， 相当亮眼。 导语：A股上市至今股价飙升逾10倍。 值得注意的是，百利天恒又在日前整出了一个"大消息"。 值得注意的是，百利天恒的资金储备其实尚算充裕。数据显示，截至2025年三季度末货币资金达 60.86亿元。不过，创新药的研发及商业化极其"烧钱"，多储备储备资金弹药也是很有必要的。 百利天恒在公告中称， 此次申请注册发行债务融资工具，有利于优化公司债务结构， 促进公司 高质量、稳健、可持续发展，符合公司及全体股东整体利益，不存在损害中小股东利益的情形。 不过，这项百亿发债计划也是一把双刃剑：若能顺利落地，将为核心产品商业化、全球化布局提 供充足资金支持；但同 ...

药明康德10月29日晚间发布公告，17名股东计划自2025年11月20日起15个交易日后的3个月内，通过集中竞价和大宗 交易方式减持公司股份不超过5967.5万股，即不超过公司总股本的2%。此消息一出，第二天药明康德股价跳空低开， 盘中一度下挫超过8%。 2025年第四季度，随着美联储降息预期升温，全球生物医药投融资活动显露复苏迹象，国内CXO行业景气度预期得到 修复。然而，就在市场情绪回暖之际，部分生物医药企业的大股东减持行为再次引发投资者关注。 药明康德股东近三年间已完成的两次减持，就是一个典型的例子。 2023年4月28日，药明康德发布减持公告，公司股东计划通过集中竞价或大宗交易的方式减持公司不超过总股本3%的 股份。几个月后的8月9日，公司再发公告，拟通过同样方式减持不超过总股本1%的股份。 两次减持过后，药明康德股价均在短时间内出现大幅下挫，看似由于大股东减持引发股价暴跌，实则恰逢创新药概念 整体获利回吐。创新药概念指数从2023年4月14日1057.13高点回落至2023年8月24日的846.65，跌幅将近20%。在这个 时间段内药明康德股价仅回落13%，低于行业跌幅。 该市场分析人士表示，大股东 ...

Market Overview - The A-share market opened higher on December 19, with all three major indices rising [1] - In the market, computing hardware rebounded, with CPO and storage indices leading the gains; sectors like coal, precious metals, and shipping weakened [2] Sector Performance - The smart driving concept was notably active, with Zhejiang Shibao (002703) achieving a four-day consecutive limit-up, supported by over 220,000 buy orders [3] - The Ministry of Industry and Information Technology announced the first batch of L3-level conditional autonomous driving vehicle approvals, marking a significant step towards commercial application [4] - Zhejiang Shibao confirmed its long-term partnerships with various traditional and new car manufacturers, indicating that its products are suitable for L3 and above autonomous driving [5] Emerging Concepts - The commercial aerospace sector showed strength, with Huati Technology achieving a two-day consecutive limit-up, alongside other companies like Xinke Mobile and Guanglian Aviation [6] - The electrolytic manganese concept experienced fluctuations, with Red Star Development hitting the limit-up, driven by rising prices that reached a three-year high [9] - The controllable nuclear fusion concept saw gains, with companies like Wangzi New Materials and Changfu Co., Ltd. achieving significant increases [10] - The innovative drug sector rebounded, with Yifang Bio rising nearly 10%, alongside other pharmaceutical companies [11]

创新药概念再度走低，下半年来医药BD交易短暂真空。诺诚健华(09969)跌超3.62%；信达生物(01801) 跌2.39%。 黄金股全线走低。BOCM指数权重即将再平衡，小摩称金银面临巨量技术性抛压。紫金黄金国际 (02259)跌5.93%；紫金矿业(02899)跌4.5%。 光伏股再度走弱。光伏协会确认收储平台成立，光伏玻璃价格仍然承压。新特能源(01799)跌2%；信义 光能(00968)跌3.6%。 智通财经获悉，港股恒生指数跌1.91%，跌490点，报25138点；恒生科技指数跌2.41%。港股早盘成交 1072亿港元。 12月15日，工业和信息化部正式公布我国首批L3级有条件自动驾驶车型准入许可名单，标志着中国智 能网联汽车发展迈入实质性应用阶段。智能驾驶概念股逆市走高。浙江世宝(01057)涨13.9%、佑驾创新 (02431)涨9.88%。 甲骨文发布2026财年第二财季业绩，远逊于市场预期。光通信板块延续昨日下跌。剑桥科技(06166)、 长飞光纤光缆(06869)均跌超5%。 中兴通讯(00763)再跌超4%，豆包手机助手调整部分AI能力，公司近期宣布大额回购。 拨康视云-B(02592) ...

Group 1 - The Hang Seng Index fell by 1.91%, losing 490 points to close at 25,138 points, while the Hang Seng Tech Index dropped by 2.41% [1] - The Ministry of Industry and Information Technology of China announced the first batch of L3 conditional autonomous driving vehicle licenses, marking a significant step in the development of intelligent connected vehicles in China [1] - Smart driving concept stocks rose against the market trend, with Zhejiang Shibao increasing by 13.9% and Youjia Innovation rising by 9.88% [1] Group 2 - Innovative drug concept stocks declined, with notable drops in companies such as Innovent Biologics, which fell over 3.62%, and I-Mab, which decreased by 2.39% [1] - Gold stocks experienced a widespread decline, with Zijin Mining International dropping by 5.93% and Zijin Mining Group falling by 4.5% due to significant technical selling pressure [1] - Photovoltaic stocks weakened again, with New Special Energy down by 2% and Xinyi Solar decreasing by 3.6%, amid ongoing price pressures on photovoltaic glass [1] Group 3 - Oracle's second fiscal quarter results for 2026 fell short of market expectations, contributing to a continued decline in the optical communication sector, with Cambridge Technology and Yangtze Optical Fibre and Cable both dropping over 5% [1] - ZTE Corporation saw a decline of over 4%, with the company recently announcing a large share buyback amid adjustments to its AI capabilities [2] - Bole Technology fell by 11% following the submission of a new drug clinical trial application for its ophthalmic candidate CBT-199 in the U.S. [3] Group 4 - Hushang Ayi saw an increase of over 4% as the domestic new tea beverage brand expands into international markets, specifically Malaysia and the United States [4]

智通财经APP获悉，创新药概念股再度走低，截至发稿，诺诚健华(09969)跌5.09%，报12.86港元；石药 集团(01093)跌3.99%，报7.21港元；信达生物(01801)跌3.36%，报79港元。 中邮证券指出，下半年以来，国内的BD出海交易虽有短暂真空，但仍在持续，Q4以来亦诞生了多个 MNC为合作方的交易。该行认为，海外MNC的购买行为系对国内创新药公司创新研发的实力的背书认 可。进一步看，该行认为系中国创新药产业链能力、管线数量和质量、研发效率在全球的强大竞争优势 催生出的结果，坚定看好长期的产业趋势。 值得关注的是，A股创新药大牛股一品红昨日意外跌停，今早再跌超13%。该公司参股的美国Arthrosi公 司收到收购要约，交易总金额最高可达15亿美元。有分析称，一品红的交易可能改变了一些市场预期。 此前市场预期的这个标的是按现在的收购价进行BD，但现在是直接卖出。而此前，股价上涨太多，并 且反应的是BD，现在预期走弱，故而股价跌停。 ...